Verrica Pharmaceuticals (VRCA) Q3 2026 earnings review
Verrica collects more per dose, but its cash horizon shrinks
Verrica Pharmaceuticals, the maker of the Ycanth skin-infection treatment, collected more money per dose even as doctor dispensing slipped. U.S. product sales rose 12% from last quarter to $6 million because chief executive Jayson Rieger pared back co-pay discounts and shipped more inventory to distributors. Total revenue dropped 52% from a year ago only because last year included a one-time $10 million payment from its Japanese partner, Torii.
| Total revenue (excluding last year's $10M one-off milestone) | $6.9M +59% from a year ago by our math (reported: -52%) |
|---|---|
| U.S. Ycanth net product revenue | $5.7M +58% from a year ago, +12% from last quarter |
| Dispensed applicator units | 19,135 +36% from a year ago, -2.5% from last quarter |
| Cash runway outlook | Cut to Q4 2027 prior plan: into 2028 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because higher revenue per applicator and an earlier clinical readout merely offset a shorter cash runway and a dip in dispensed doses. By our math, revenue per dispensed unit rebounded to $298, and finishing enrollment in the first common warts trial pulled data forward to early 2027. The bad news: unlocking the rest of the chairman's $28 million loan still left the cash forecast shorter, moving back from 2028 into late 2027.
The question now is whether third-quarter sales reflect healthier pricing or just distributor shipments ahead of demand. If pharmacy routing fixed the discounts, revenue per dose stays near $300 as units recover; if shipments outran doctors, unpaid bills of $12 million will force slower orders. Fourth-quarter dispensed units and receivables will settle it.
🐂 Bull Case
Lower Co-Pay Spending Lifted Revenue Per Applicator
Verrica sells Ycanth, an applicator-delivered skin treatment for the viral infection molluscum contagiosum. For the past year, rising patient rebates ate into the money the company kept per dose. This quarter, chief executive Jayson Rieger said "during the quarter we began realizing the benefits of these efforts with improvement in gross to net" after routing prescriptions through its YCanthRx pharmacy hub.
U.S. Ycanth net product revenue rose 11.9% from last quarter to $5.7 million, and jumped 57.9% from a year ago. The dermatologist group attributed the gain to "increased deliveries of YCANTH to our distribution partners as well as improved yield from reduced spending on our co-pay assistance program". By our math, net product revenue per dispensed applicator climbed to $298, up from $260 last quarter and $256 a year ago.
That rebound lifted product gross margin by 10.7 percentage points from a year ago to 89.8%, because the cost of making the product fell to 8.4% of total revenue. One quarter eases the pricing concern, but does not settle it because distributor deliveries also boosted the top line.
What to watch: gross-to-net reserve balances in the third-quarter filing and fourth-quarter revenue per applicator. A second quarter near $300 per unit would show that lower co-pay spending is permanent rather than a distributor stocking blip.
Common Warts Trial Finishes Enrollment Early
Verrica wants federal approval to sell Ycanth for common warts, a skin condition affecting about 22 million Americans with no approved prescription drug. The drugmaker is running two late-stage clinical trials in the United States and Japan alongside its Japanese partner, Torii Pharmaceutical.
In August, the company finished enrolling patients in COVE-2, the first of those two trials, "after an interim analysis recommended that no additional patients were needed to power the trial", Rieger said. That moved the expected readout for the first trial forward to the first quarter of 2027, while the second trial, COVE-3, passed 50% enrollment and stays on track for mid-2027.
Stopping enrollment early after an interim check saves time and pulls the main clinical catalyst into the next few months. What to watch: topline clearance rates from the COVE-2 study in the first quarter of 2027. A clean statistical win would validate Ycanth in a patient pool nearly four times larger than its current market.
🐻 Bear Case
Chairman's Loan Unlocks $15M, Yet Runway Shrinks
Verrica relies on a $27.5 million credit facility from an entity controlled by its chairman, Paul B. Manning, to fund its operations. The standing bull case views this related-party debt as a bridge to clinical data without issuing new shares, while the bear case focuses on cash burn and senior debt sitting ahead of stockholders. Rieger said "we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program".
On October 22, the company hit its operational targets to unlock the remaining $15.0 million of the loan, after putting $11.6 million of net term loans on its balance sheet during the third quarter. Even with full access to the loan, Verrica now says its cash runway extends into the fourth quarter of 2027, whereas last quarter it projected cash into 2028.
That shortened timeline cuts against the narrative of an expanding cushion. By our math, Verrica burned about $8.4 million of cash in the quarter, since cash rose by only $3.2 million to $14.4 million despite the new borrowing. The forecast also stands "without giving effect to any potential clinical trial costs related to the study of VP-315 for the treatment of Gorlin syndrome".
What to watch: fourth-quarter ending cash and any trial budget for Gorlin syndrome. Spending money on a new cancer study or missing the mid-2027 readout schedule would leave the drugmaker needing fresh cash before its common warts approval.
Dispensed Units Slipped and Unpaid Bills Piled Up
Dispensed applicator units measure how many Ycanth doses pharmacies and clinics actually ship or sell to doctors, making them the clearest gauge of underlying patient demand. Earlier this year, a redesigned commercial team drove a 28.3% quarterly jump in dispensed doses, which supported the view that prescription demand was speeding up.
In the third quarter, dispensed units fell 2.5% from the second quarter to 19,135, and annual growth slowed to 35.8% from 46.1% last quarter. Management blamed "summer travel seasonality, with both patients and providers" for the dip, yet net product revenue still rose 11.9% over the same period because Verrica shipped more boxes to its distributors.
Shipping more product to distributors while doctor dispensing drops explains why unpaid customer bills keep rising. Accounts receivable reached $11.6 million in September, up 115.8% since December and equal to 204.5% of the entire quarter's net product sales by our math, so revenue growth is outrunning cash collection.
What to watch: fourth-quarter dispensed applicator units and accounts receivable once summer travel ends. If dispensed doses do not rebound above 19,626 while unpaid bills stay above two times quarterly sales, distributors may have to slow their orders.
Partner Trial Debt Doubled Since December
Under its partnership agreement, Japanese drugmaker Torii Pharmaceutical pays the first $40 million of bills for the global common warts trials. That arrangement shields Verrica's bank account today, but Verrica still owes half of those study costs and must repay Torii out of future Japanese product supply payments, royalties and milestones.
- Research and development expense: $7.6 million, up from $2.2 million a year ago
- Research and development share of revenue: 109.6%, up 94.2 percentage points from a year ago by our math
- Non-cash common warts trial increase: $3.7 million of the quarterly research spending rise
- Research and development funding liability: $10.9 million, up from $8.4 million in June and $5.1 million in December
This matters because the growing IOUs to Torii pushed total liabilities to $45.8 million and drove stockholders' equity into a $6.0 million deficit. What to watch: the research funding liability on the year-end balance sheet, as every dollar added now reduces the cash Verrica will collect from Japan after the trial ends.
Risks this quarter didn't answer
Four standing concerns from earlier quarters received no new figures in the third-quarter earnings release.
- Going-concern warning: omitted from the press release; Note 1 of the third-quarter Form 10-Q filing will show whether unlocking the $15 million loan removed the formal warning.
- Gross-to-net reserve balance: not disclosed in the release; the filing's footnote on revenue reserves will show whether higher revenue per dose came from releasing prior reserves.
- Sales force expansion and European filing: no update on the plan to reach 50 sales reps by year-end or the European molluscum application; the filing and conference call will test both.
- Revenue outlook and single-product reliance: management again gave no revenue forecast, and Ycanth still generates all commercial product sales.
👓 Other Themes
Cancer Drug Shifts Toward Rare Genetic Disease
Verrica has promoted its injected skin cancer drug, VP-315, as ready for two late-stage trials in common basal cell carcinoma. This quarter, the company shifted toward exploring VP-315 for Gorlin syndrome, a rare genetic condition that causes dozens of skin cancers and "often presenting them with substantial surgical fatigue", Rieger said. Management is still designing the trial and budget, so no late-stage cancer study has started.
💲 Other KPIs
License and collaboration revenue — payments from partner Torii for commercial Ycanth supply and milestones — dropped 88.7% from $10.7 million a year ago because last year included a one-time $10.0 million Japanese approval payment. Excluding that one-off payment, ongoing supply revenue grew 65.1% from $0.7 million a year ago and rose from $0.8 million last quarter.
Selling, general and administrative spending — sales reps, marketing and corporate overhead — rose 10.1% from $9.4 million a year ago, but held steady against $10.35 million last quarter. Excluding $1.4 million of non-cash stock compensation, overhead was flat from a year ago, though the lower total revenue base pushed it up by 84.2 percentage points of revenue.
Weighted average shares more than doubled, rising 124.5% from 9.49 million a year ago after the dermatology company sold stock and warrants in a November 2025 private placement to pay off its old debt. The share count has stayed unchanged at 21.31 million for three straight quarters.
🔮 Guidance
Cut. The operational plan now sees cash and the full $27.5 million related-party loan funding the business into the fourth quarter of 2027, down from last quarter's target of into 2028. The shorter horizon reflects ongoing cash burn and still excludes any spending on a potential Gorlin syndrome trial for VP-315.
Raised. Management pulled the expected readout for the first pivotal study, COVE-2, forward into the first quarter of 2027 after finishing patient enrollment in August following a positive interim review. The second trial, COVE-3, remains over 50% enrolled with results still planned for mid-2027.
❓ Key Questions
Why do unpaid bills exceed two quarters of sales?
Accounts receivable reached $11.6 million at the end of September, more than double third-quarter net product revenue of $5.7 million. Investors need to know whether distributor payment terms have stretched beyond 60 days or if distributors are holding excess inventory.
Did reserve releases boost revenue per applicator this quarter?
Net product revenue rose 11.9% from last quarter even though dispensed applicator doses fell 2.5%. Management did not disclose its gross-to-net reserve balances in the release, leaving open how much of the $298 per-unit yield came from one-time reserve adjustments.
Why did the cash runway shrink from 2028 to late 2027?
Verrica unlocked the final $15.0 million tranche of its credit facility in October, fulfilling the exact assumption behind last quarter's forecast of cash into 2028. Management did not explain which costs rose to pull that runway back into the fourth quarter of 2027.
What will the Gorlin syndrome study cost, and what happens to BCC?
The company is now designing a trial of VP-315 in rare Gorlin syndrome while leaving its cash runway forecast exclusive of any VP-315 trial costs. Investors need the trial budget and clarity on whether the two larger basal cell carcinoma studies are shelved.